Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis
…, DE Jonas, LJ Lux, P Thieda, BL Jonas… - Annals of internal …, 2008 - acpjournals.org
… group C, and P < 0.001 for group B vs. group D). Patients given initial combination therapy
of methotrexate, sulfasalazine, and tapered high-dose prednisone or initial combination …
of methotrexate, sulfasalazine, and tapered high-dose prednisone or initial combination …
The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis.
… Rituximab binds specifically to the antigen CD20, resulting in the depletion of B cells. All
these actions greatly reduce various inflammatory and immunological responses. Biologics …
these actions greatly reduce various inflammatory and immunological responses. Biologics …
[HTML][HTML] How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia
BA Jonas, DA Pollyea - Leukemia, 2019 - nature.com
Acute myeloid leukemia (AML) is associated with poor outcomes, especially in older patients
in whom the disease is most common. B-cell lymphoma 2 (BCL-2) is an antiapoptotic …
in whom the disease is most common. B-cell lymphoma 2 (BCL-2) is an antiapoptotic …
[HTML][HTML] Azacitidine and venetoclax in previously untreated acute myeloid leukemia
CD DiNardo, BA Jonas, V Pullarkat… - … England Journal of …, 2020 - Mass Medical Soc
Background Older patients with acute myeloid leukemia (AML) have a dismal prognosis,
even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had …
even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had …
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Older patients with acute myeloid leukemia (AML) respond poorly to standard induction
therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells and …
therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells and …
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised …
… B (four in group A and two in group B) had venetoclax dose interruptions (one in group A and
one in group B … interruptions (nine in group A and eight in group B), and two (8%) of these …
one in group B … interruptions (nine in group A and eight in group B), and two (8%) of these …
Are symptoms of anxiety and depression risk factors for hypertension? Longitudinal evidence from the National Health and Nutrition Examination Survey I …
BS Jonas, P Franks, DD Ingram - Archives of family medicine, 1997 - europepmc.org
Objective To test the hypothesis that symptoms of anxiety and depression increase the risk
of experiencing hypertension, using the National Health and Nutrition Examination I …
of experiencing hypertension, using the National Health and Nutrition Examination I …
Do depression symptoms predict early hypertension incidence in young adults in the CARDIA study?
K Davidson, BS Jonas, KE Dixon… - Archives of internal …, 2000 - jamanetwork.com
Background Hypertension has been linked to several psychological factors, including
depression, but the relation between hypertension incidence and depressive symptoms has not …
depression, but the relation between hypertension incidence and depressive symptoms has not …
Symptoms of depression as a prospective risk factor for stroke
BS Jonas, ME Mussolino - Psychosomatic medicine, 2000 - journals.lww.com
Objective The objective of this study was to assess baseline levels of depression as a risk
factor for stroke among white and black men and women. Methods A population-based cohort …
factor for stroke among white and black men and women. Methods A population-based cohort …
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open …
… Other exclusion criteria were receipt of major surgery or radiotherapy within 4 weeks of
screening; active uncontrolled infection, hepatitis B or C, or clinically relevant liver disease; …
screening; active uncontrolled infection, hepatitis B or C, or clinically relevant liver disease; …